NasdaqGM - Nasdaq Real Time Price • USD
Fulgent Genetics, Inc. (FLGT)
As of 10:26 AM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | -0.32 | -0.28 | -1.06 | -0.76 |
| Low Estimate | -0.35 | -0.29 | -1.08 | -1.04 |
| High Estimate | -0.3 | -0.27 | -1.05 | -0.38 |
| Year Ago EPS | -0.22 | -0.08 | -0.41 | -1.06 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | 65.36M | 69.06M | 279.36M | 321.38M |
| Low Estimate | 64.17M | 68.18M | 277.8M | 310.55M |
| High Estimate | 67.3M | 69.9M | 280.18M | 339.5M |
| Year Ago Sales | 66.17M | 67.85M | 289.21M | 279.36M |
| Sales Growth (year/est) | -1.20% | 1.80% | -3.40% | 15.00% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.43 | -0.33 | -0.33 | -0.29 |
| EPS Actual | -0.22 | -0.08 | -0.39 | 0.28 |
| Difference | 0.21 | 0.25 | -0.06 | 0.57 |
| Surprise % | 48.80% | 75.80% | -18.20% | 196.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.32 | -0.28 | -1.06 | -0.76 |
| 7 Days Ago | -0.32 | -0.28 | -1.06 | -0.76 |
| 30 Days Ago | -0.32 | -0.28 | -1.06 | -0.76 |
| 60 Days Ago | -0.23 | -0.22 | -0.95 | -0.65 |
| 90 Days Ago | -0.23 | -0.22 | -0.95 | -0.65 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | FLGT | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -45.50% | -- | -- | 0.80% |
| Next Qtr. | -250.00% | -- | -- | 9.60% |
| Current Year | -158.50% | -- | -- | 4.50% |
| Next Year | 28.30% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -52.25% | -- | -- | 11.09% |
| Past 5 Years (per annum) | 67.92% | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Maintains | Piper Sandler: Neutral to Neutral | 3/6/2024 |
| Initiated | UBS: Neutral | 12/7/2023 |
| Maintains | Piper Sandler: Neutral to Neutral | 10/16/2023 |
| Maintains | Credit Suisse: Outperform | 3/2/2023 |
| Downgrade | Piper Sandler: Overweight to Neutral | 12/8/2022 |
| Initiated | Raymond James: Outperform | 11/18/2022 |
Related Tickers
VCYT Veracyte, Inc.
19.30
+0.49%
MYGN Myriad Genetics, Inc.
18.50
-0.05%
CDNA CareDx, Inc
8.18
+1.36%
DMTK DermTech, Inc.
0.6111
+3.40%
GH Guardant Health, Inc.
16.46
-1.26%
CRL Charles River Laboratories International, Inc.
229.42
+0.82%
CSTL Castle Biosciences, Inc.
19.14
-0.31%
MEDP Medpace Holdings, Inc.
372.00
-0.62%
MTD Mettler-Toledo International Inc.
1,197.16
+0.39%
WAT Waters Corporation
295.87
+0.56%